Skip to main content

Advertisement

SpringerLink
Log in

Educating Patients About the Benefits and Drawbacks of Hormone Replacement Therapy

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Hormone replacement therapy (HRT) influences many aspects of health: climacteric symptoms, osteoporosis, cardiovascular disease, breast and endometrial cancer, thrombosis and emboli, and Alzheimer’s disease. A decision to use HRT may depend on a woman’s individual views of the menopausal transition, the postmenopause and its consequences. It is therefore useful that the health provider inquires about and discusses these issues in a cultural and family context.

Health providers and patients should be thoroughly informed about the symptoms associated with hormonal deprivation, the associated risks of osteoporosis and cardiovascular disease, and the potential of HRT to prevent these afflictions. Recent studies suggest that HRT might be particularly beneficial in women who have an increased risk for cardiovascular disease (because of left ventricular hypertrophy, diabetes mellitus, hypertension or hypercholesterolaemia, or because they smoke) or osteoporosis. In women who are undecided about HRT, a low bone mineral density measurement might help convince them to start using, or to continue using, HRT.

There is also a need to discuss with the patient the effect of HRT on cancer risk. In most instances, women can be reassured about the risk of endometrial cancer. The risk of breast cancer should be carefully considered and discussed with each patient before beginning HRT. In most cases, HRT should not be withheld because of fears about breast cancer, because the protective effects of HRT against cardiovascular disease and osteoporosis outweigh the possible increased risk of breast cancer.

When HRT is prescribed, individual regimens should be discussed with the patient, who must be warned of the possible adverse effects. In older women, HRT can be started at half the normal dosage and tolerability assessed before increasing the dosage further.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 647–50

    Google Scholar 

  2. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994; 62Suppl. 2: 176S–9S

    Google Scholar 

  3. Rozenberg S, Liebens I, Vandromme J, et al. Cardiovascular protection by estrogen: a hemodynamic mechanism? Int J Fertil Menopausal Stud 1994; 39: 36–42

    PubMed  Google Scholar 

  4. Voigt LF, Weiss NS, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–7

    Article  PubMed  CAS  Google Scholar 

  5. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995; 85: 304–13

    Article  PubMed  CAS  Google Scholar 

  6. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93

    Article  PubMed  CAS  Google Scholar 

  7. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–80

    Article  PubMed  CAS  Google Scholar 

  8. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996; 156(19): 2213–7

    Article  PubMed  CAS  Google Scholar 

  9. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37

    PubMed  CAS  Google Scholar 

  10. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277: 1140–7

    Article  PubMed  CAS  Google Scholar 

  11. Rozenberg S, Vandromme J, Ham H. Facilitating patient-specific decisions regarding hormone replacement therapy. JAMA 1997; 278: 475

    Article  PubMed  CAS  Google Scholar 

  12. Rozenberg S, Kroll M, Vandromme J. Decision factors influencing hormone substitution therapy prescription. Br J Obstet Gynaecol 1996; 103(13): 92–8

    PubMed  Google Scholar 

  13. Schneider HPG. Cross-national study: women’s use of HRT in Europe. Int J Fertil Menopausal Stud 1997; 42: 365–75

    Google Scholar 

  14. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women’s characteristics. J Clin Epidemiol 1993; 46: 211–9

    Article  PubMed  CAS  Google Scholar 

  15. Rozenberg S, Vandromme J, Kroll M, et al. Compliance of hormone replacement therapy. Int J Fertil Menopausal Stud 1995; 40(1): 23–32

    PubMed  Google Scholar 

  16. Brett KM, Madams JH. Differences in use of postmenopausal hormone replacement therapy by Black and White women. Menopause 1997; 4(2): 66–70

    Article  Google Scholar 

  17. Boulet MJ, Oddens BJ. Experiences and views of women and physicians concerning climacteric complaints: information provision, knowledge and medication use. In: Boulet MJ, Oddens BJ, editors. International Health Foundation 1994; 2: 8–12

    Google Scholar 

  18. Griffiths F. Women’s health concerns: is the promotion of hormone replacement therapy for prevention important to women? Fam Pract 1995 Mar; 12(1): 54–9

    Article  PubMed  CAS  Google Scholar 

  19. Millonig VL. Menopause: health promotion opportunities for the occupational health nurse. AAOHN J 1996; 44(12): 585–95

    PubMed  CAS  Google Scholar 

  20. Robinson A. Kit helps physicians, women work together to weigh HRT risk, benefits. Can Med Assoc J 1997; 156(2): 248–50

    CAS  Google Scholar 

  21. Porter M, Penney GC, Russell D, et al. A population based survey of women’s experience of the menopause. Br J Obstet Gynaecol 1996; 103: 1025–8

    Article  PubMed  CAS  Google Scholar 

  22. Barlow DH, Grosset KA, Hart H, et al. A study of the experience of Glasgow women in the climacteric years. Br J Obstet Gynaecol 1989; 96: 1192–7

    Article  PubMed  CAS  Google Scholar 

  23. Carr BR. HRT management: the American experience. Eur J Obstet Gynecol Reprod Biol 1996; 64Suppl. 1: S17–20

    Article  PubMed  CAS  Google Scholar 

  24. Ringa V, Ledésert B, Bréart G. Determinants of hormone replacement therapy among postmenopausal women enrolled in the French GAZEL cohort. Osteoporos Int 1994; 4: 16–20

    Article  PubMed  CAS  Google Scholar 

  25. Rubin SM, Cummings SR. Results of bone densitometry affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 1992; 116: 990–5

    PubMed  CAS  Google Scholar 

  26. Silverman SL, Greenwald M, Klein RA, et al. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol 1997; 89: 321–5

    Article  PubMed  CAS  Google Scholar 

  27. Isaacs AJ, Britton AR, McPherson K. Utilisation of hormone replacement therapy by women doctors. BMJ 1995; 311: 1399–401

    Article  PubMed  CAS  Google Scholar 

  28. Report of a World Health Organization (WHO) Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994; 843: 5–6

    Google Scholar 

  29. Rozenberg S, Kroll M, Vandromme J, et al. Factors influencing the prescription of hormone replacement therapy. Obstet Gynecol 1997; 90: 387–91

    Article  PubMed  CAS  Google Scholar 

  30. Salamone LM, Pressman AR, Seeley DG, et al. Estrogen replacement therapy: a survey of older women’s attitudes. Arch Intern Med 1996; 156: 1293–7

    Article  PubMed  CAS  Google Scholar 

  31. Posthuma WDW, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effects of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1268–9

    Article  PubMed  CAS  Google Scholar 

  32. Norman SG, Studd JWW. A survey of views on hormone replacement therapy. Br J Obstet Gynecol 1994; 101: 879–87

    Article  CAS  Google Scholar 

  33. Hemminki E, Topo P, Malin M, et al. Physicians’ views on hormone therapy around and after menopause. Maturitas 1993; 16: 163–73

    Article  PubMed  CAS  Google Scholar 

  34. Cauley JA, Cummings SR, Black DM, et al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163: 1438–44

    PubMed  CAS  Google Scholar 

  35. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76: 290–5

    PubMed  CAS  Google Scholar 

  36. Christiansen C. Hormone replacement therapy for established osteoporosis in elderly women. Baillieres Clin Obstet Gynaecol 1991; 5(4): 853–6

    Article  PubMed  CAS  Google Scholar 

  37. Cummings SR. Bone mass and bone loss in the elderly: a special case? Int J Fertil 1993; 38: 92–7

    Google Scholar 

  38. Black DM. Screening and treatment in the elderly to reduce osteoporotic fracture risk. Br J Obstet Gynecol 1996; 103: 2–8

    Article  Google Scholar 

  39. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women: study of osteoporotic fractures research group. Ann Intern Med 1995; 122: 9–16

    PubMed  CAS  Google Scholar 

  40. Rozenberg S, Ylikorkala O, on behalf of the international group of investigators. Comparison of continuous and sequential transdermal progesterone with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding pattern and serum lipids. Int J Fertil Menopausal Stud 1997; 42: 376–87

    CAS  Google Scholar 

  41. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol 1990; 75Suppl. 4: 77S–80S

    PubMed  CAS  Google Scholar 

  42. Van de Weijer PHM, Barentsen R, Keenmans P. Hormone replacement therapy and the vaginal bleeding issue. Gynecol Endocrinol 1998; 12(3): 9–15

    Google Scholar 

  43. Magos AL, Brincat M, Studd JWW, et al. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985; 65: 496–9

    PubMed  CAS  Google Scholar 

  44. Mattsson LA, Milsom I, Stadberg E. What do women want? Br J Obstet Gynaecol 1996; 103Suppl. 13: 104–6

    PubMed  Google Scholar 

  45. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–90

    Article  PubMed  CAS  Google Scholar 

  46. Sillero Arenas M, Delgado Rodriguez M, Rodrigues Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286–94

    PubMed  CAS  Google Scholar 

  47. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137–42

    Article  PubMed  CAS  Google Scholar 

  48. Steinberg KK, Thacker SB, Smith SJ. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–90

    Article  PubMed  CAS  Google Scholar 

  49. Cobleigh MA, Berris RF, Bush T, et al. The Breast Cancer Committees of the Eastern Cooperative Oncology Group. Estrogen replacement therapy in breast cancer survivors: a time for change. JAMA 1994; 272: 540–5

    Article  PubMed  CAS  Google Scholar 

  50. Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: a survey of women’s knowledge and attitudes. Arch Intern Med 1989; 149: 133–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interdisciplinary Group on Osteoporosis, Free Universities of Brussels (VUB-ULB), St Peter Hospital, rue Haute 322, B-1000, Brussels, Belgium

    Serge Rozenberg, Jorge Barudy Vasquez, Jean Vandromme & Marie Kroll

Authors
  1. Serge Rozenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Barudy Vasquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean Vandromme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie Kroll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Serge Rozenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rozenberg, S., Vasquez, J.B., Vandromme, J. et al. Educating Patients About the Benefits and Drawbacks of Hormone Replacement Therapy. Drugs & Aging 13, 33–41 (1998). https://doi.org/10.2165/00002512-199813010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199813010-00004

Keywords

Search

Navigation